A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

The US FDA has granted approval for a label update to Eli Lilly and Company's Amyvid (florbetapir F 18 injection) for use ...

Eli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following ...

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...